Prialt Review Shows Swing In FDA’s Statistical Preference
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA reanalyzed Elan's Prialt (ziconotide) data using its now-preferred conservative technique for imputation of missing data in chronic pain trials to assuage concerns that the protocol-specified analysis could magnify treatment effect
You may also be interested in...
FDA Advice On Missing Data May Be To Avoid Missing It In The First Place
FDA officials respond to the recommendations of a National Research Council Panel on handling missing data in clinical trials, giving early indications of how FDA could be viewing a forthcoming guidance on the issue.
Missing Clinical Trial Data: "Mixed Model" Approach Gains Ground At FDA
Clinical trial sponsors should adopt a mixed statistical model to cope with missing data rather than relying on the "last observation carried forward" model that was formerly perceived as regulators' favorite
Statistics Bedeviled But Did Not Derail Cymbalta Fibromyalgia Approval
Lilly ran into one review issue with its fibromyalgia NDA for Cymbalta (duloxetine) because it did not adhere to a "well established policy" of the FDA division responsible for analgesic drugs regarding imputation of missing data, a recurring statistical issue in pain drug reviews, review documents show